Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
Show more...
CEO
Richard Chin
従業員
63
国
US
上場銘柄
0 Comments
意見をシェア
FAQ
Kindred Biosciencesの株価は今日いくらですか?▼
KIN の現在価格は $9.25 USD で、過去24時間で +0.11% 上昇しました。チャートで Kindred Biosciences 株価の動きを詳しく確認しましょう。